A Double‐Blind Randomized Study Comparing the Efficacy and Safety of a Composite vs a Conventional Intravenous Fat Emulsion in Postsurgical Gastrointestinal Tumor Patients

Ma, Cheng‐Jen; Sun, Lulu; Chen, Fang‐Ming; Lu, Chien‐Yu; Shih, Yuh-Chuan; Tsai, Hsiang-Lin; Chuang, Jui-Fen; Wang, Jaw‐Yuan

doi:10.1177/0884533611436115

Cited by 36 publications

(53 citation statements)

References 36 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the potential to reduce thrombosis, studies of platelet function with parenteral fish oil have been undertaken in adult humans, particularly in the setting of surgical interventions 16 . ‐ 19 While these studies have been reassuring, it must be noted that the doses are markedly lower than those advocated for infants with IFALD given PN exclusively with fish oil.…”

Section: Discussionmentioning

confidence: 99%

Platelet Arachidonic Acid Deficiency May Contribute to Abnormal Platelet Function During Parenteral Fish Oil Monotherapy in a Piglet Model

Turner

Field

Goruk

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet Arachidonic Acid Deficiency May Contribute to Abnormal Platelet Function During Parenteral Fish Oil Monotherapy in a Piglet Model

Turner

Field

Goruk

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…Although the current data available for Smoflipid are from short‐term clinical trials (Table 1), 91 – 103 the use of MO IFE is theoretically much more physiologically similar to normal dietary human consumption and human milk (Table 2). 19 , 96 , 101 , 102 , 104 – 105 It appears to use the advantages of each oil while reducing the disadvantages (ie, SO and inflammation, FO and low number of calories, respectively) of relying predominately on 1 oil for the IFE source. The benefits of this approach seem especially evident in the impact of IFEs on liver enzymes, with multiple studies showing either a decrease or a smaller increase with MO IFE use 91 – 93 , 95 , 98 – 100 .…”

Section: Mixed‐oil Ifementioning

confidence: 99%

Emergence of Mixed‐Oil Fat Emulsions for Use in Parenteral Nutrition

Mundi

Martindale

Hurt

2017

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Since early work by Wretlind and Schuberth led to the development of a stable and safe intravenous fat emulsion (IFE) using soybean oil (SO) and egg phospholipid emulsifier, IFEs have become a crucial source of essential fatty acids and nonprotein energy in parenteral nutrition. However, largely due to their high ω-6 polyunsaturated fatty acid (PUFA) and phytosterol content, SO IFEs have been associated with complications, including a proinflammatory profile and hypertriglyceridemia, as well as intestinal failure-associated liver disease. Subsequent generations of IFEs have used other sources of triglycerides, including medium-chain triglycerides (MCTs), olive oil (OO), and fish oil (FO), to reduce the SO component. Although these IFEs showed some improvement in complications compared with SO IFE, the quest to develop an IFE with a better side effect profile and beneficial physiologic effects led to the development of a mixed-oil (MO) IFE (Smoflipid; 30% SO, 30% MCTs, 25% OO, and 15% FO) that was recently approved by the Food and Drug Administration. The use of a MO approach is theoretically and intuitively more physiologically similar to normal dietary human consumption. Although the data are from small, short-term trials, MO IFE results thus far have been promising, with some studies showing improved liver function tests, improvement in triglycerides, higher ω-3/ω-6 PUFA ratio, and higher α-tocopherol. Larger long-term studies are needed to ensure these theoretical benefits lead to significant improvement in clinical outcomes.

show abstract

“…Regarding the rest of clinical studies, six (46%) resulted in similar clearance to control emulsions (6,14,16,20,30,34), and only in one (8%) of them (7) triglyceridemia increased in the experimental group.…”

Section: Effects Unrelated To Anti-inflammation Of Lipid Emulsions Comentioning

confidence: 99%

“…Several prospective studies have been published assessing the preventive effect of IVLEs containing FO on alterations in LETs or PNALD (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Characteristics of these studies are shown in table I.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

See 1 more Smart Citation

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Joaquín¹,

Florit-Sureda²

2017

Nutr Hosp

View full text Add to dashboard Cite

Mateu-de-Antonio J, Florit-Sureda M. Effects unrelated to anti-infl ammation of lipid emulsions containing fi sh oil in parenteral nutrition for adult patients. Nutr Hosp 2017;34:193-203 ResumenSe han publicado varias revisiones y metaanálisis sobre la modulación de las respuestas infl amatorias e inmunológicas por la administración de ácidos grasos poliinsaturados (AGPI) omega-3. Sin embargo, los AGPI omega-3 ejercen otras acciones no directamente relacionadas con estas respuestas. El objetivo de este trabajo es revisar los efectos de las emulsiones lipídicas intravenosas (ELIV) que contienen aceite de pescado (AP) en la nutrición parenteral (NP) de pacientes adultos. Estas emulsiones pueden tener un papel importante en la prevención de las alteraciones del perfi l hepático o de la enfermedad hepática asociada a la NP (EHANP) en comparación con las ELIV sin AP. Los estudios que usaron dosis ≥ 0,150 mg/kg/día presentaron resultados más positivos que aquellos con dosis menores. Una vez se ha presentado la EHANP, el uso de una ELIV compuesta exclusivamente de AP, a dosis de 0,25-1 g de AP/kg/día durante varias semanas, podría atenuar o incluso revertir la alteración hepática y la colestasis cuando la administración de la NP es crónica. Las ELIV con AP parecen tener un aclaramiento plasmático más rápido, lo que podría suponer una ventaja en ciertos pacientes. Algunos estudios también sugieren que estas emulsiones podrían mejorar la función respiratoria. En general, estas ELIV que contienen AP son muy seguras, no aumentan el estrés oxidativo e incluso incrementan el nivel de alfa-tocoferol plasmático. Asimismo, no alteran la sensibilidad a la insulina o el control glicémico y tampoco se ha demostrado que afecten clínicamente a la agregación plaquetaria o a la hemostasia. En conclusión, el uso de ELIV con AP en la NP podría suponer algunas ventajas frente a la ELIV sin AP, además de la modulación de la respuesta infl amatoria sistémica. AbstractSeveral reviews and meta-analyses on modulated infl ammatory and immunologic responses after the administration of omega-3 polyunsaturated fatty acids (PUFAs) in different diseases and conditions have been published. However, omega-3 PUFAs exert several other actions which are not directly related to immunologic or infl ammatory responses. The aim of this paper was to review the effects which are not directly related to immunologic and infl ammatory responses of intravenous lipid emulsions (IVLEs) containing fi sh oil (FO) in parenteral nutrition (PN) for adult patients. IVLEs containing FO could have a role in the prevention of alterations in liver enzyme tests (LETs) or PN-associated liver disease (PNALD). Studies using FO doses of ≥ 0.150 mg/kg/day or IVLEs with high FO concentration reported more positive results than those with lower doses. Once PNALD was developed, the use of IVLEs exclusively composed of FO at doses of 0.25-1 g of FO/kg/day for several weeks could attenuate or even eradicate cholestasis and liver alteration. IVLEs containing FO seemed to have faster...

show abstract

A Double‐Blind Randomized Study Comparing the Efficacy and Safety of a Composite vs a Conventional Intravenous Fat Emulsion in Postsurgical Gastrointestinal Tumor Patients

Abstract: composite IVFE was comparable with conventional LCT/MCT IVFE in efficacy, safety, tolerance, and clinical outcomes in surgical GI tumor patients.

Cited by 36 publications

References 36 publications

Platelet Arachidonic Acid Deficiency May Contribute to Abnormal Platelet Function During Parenteral Fish Oil Monotherapy in a Piglet Model

Platelet Arachidonic Acid Deficiency May Contribute to Abnormal Platelet Function During Parenteral Fish Oil Monotherapy in a Piglet Model

Emergence of Mixed‐Oil Fat Emulsions for Use in Parenteral Nutrition

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Contact Info

Product

Resources

About